Answers are grounded in this paper and cite their sources.
BREAKFAST SESSION at the Association of Academic European Urologists, COPENHAGEN 2025 Transfer of knowledge from clinical trials into daily practice is crucial to improve medical care. Despite the presence of a multitude of guidelines in the field of urology, often the clinical needs for disease management are not met. Knowledge gaps defined as the difference between what we know and what we do can be divided into: (1) the absence of clear recommendations in guidelines for specific medical conditions or (2) the absence of implementation of guidelines recommendations into clinical practice. In case of the former, the unmet needs do frequently lead to consensus statements on practical question where experts fill the knowledge gap between guideline recommendations and clinical practice.1 During the consensus finding, statements on the topic are composed that address the unmet needs to come to guidance in those clinical questions where high level of scientific evidence is needed. The frequent publication of consensus statements within a specific clinical domain may indicate either a lack of sufficient high-quality clinical trial evidence to support robust guideline development or the absence of formally endorsed guidelines. In such contexts, consensus documents serve as interim tools to harmonize clinical practice under conditions of evidentiary uncertainty. In the field of prostate cancer, an example of the role of consensus finding and guidance can be found in management of prostate cancer and the role of prostate-specific membrane antigen positron emission scanning. Although strongly recommended in the EAU and other guidelines for staging of prostate cancer, a disclaimer in the EAU prostate cancer guidelines also states that “… the ideal management of patients diagnosed as metastatic by these more sensitive tests is yet unknown.”2 The Advanced Prostate Cancer Consensus Conference voting results can help physicians tailor treatment where recommendations do not provide the level of detail needed in clinical practice.1 Moreover, knowledge gaps surface among the statements where experts, based on the available evidence and recommendations, cannot provide a consensus-based statement and clearly more specific clinical trials are needed. A second type of knowledge gap is the difference between recommendation and actual clinical practice. In the EAU guidelines on urolithiasis, the use of a double J-stent is not routinely recommended, the guidelines explicitly state: “do not insert a stent in uncomplicated ureteroscopy.” Still, surveys reported up to 92% of urologists continue inserting stents in most uncomplicated cases. Here, clearly clinical practice is not adapting, despite the available high-level evidence. Surgeons stent uncomplicated cases to mitigate perceived risks (“just in case” practice), and patients bear the symptomatic and psychological burden.3 Clearly, every clinical situation leaves room for individual judgement; however, we should avoid leaving room for neglect. The field of urolithiasis is characterized by extreme diversity, and the most appropriate way to address the individual patient is through a personalized stone approach. We acknowledge that evidence base for personalized treatment approaches is still developing; however, when solid data exist,4 “just in case practice” seems inappropriate when significant quality of life problems are at stake for the patients.5 Similar gaps between guideline recommendation and clinical practice can be observed in the field of bladder cancer management.6 EAU guidelines on muscle invasive bladder cancer shifted from cystectomy as the gold standard of treatment toward a recommendation where both radical cystectomy and trimodal bladder-preserving chemoradiotherapy should be offered as equal options. Despite this strong recommendation, still most patients are treated with cystectomy according to recent studies. Similarly, the use of neoadjuvant systemic chemotherapy was shown to improve outcome after cystectomy for T2-T4 bladder cancer and recommended in both the EAU and AUA guidelines.7,8 However, national registries on both sides of the Atlantic Ocean reported the use of neoadjuvant chemotherapy in only a minority of cases with a wide variation of use among institutes.9,10 The knowledge gaps concern both patients and medical professionals. Deviations of disease management from that what is recommended in guidelines can lead to confusion and rarely indictments. In most countries that what is written in guidelines is not binding in court but is regarded as a professional standard. For proper shared decision-making, both patients and medical professionals do require recommendations in guidelines to be available and transparent to avoid confusion. To recalibrate the transfer of knowledge from science to practice and bridge the knowledge gap the EAU guidelines office published their strategy for the 2022 to 2027.11 Now, more than halfway in this timeframe, steps have been made to obtain their goals of more dynamic, collaborative, and real-world evidence-based guidelines with high uptake and adherence. Still clinical trial results take time to deliver, and trial designs do not always meet criteria for rapid recommendation drafting. Besides prospective evidence, performance monitoring of prospectively gathered data can aid in quality control directly while also providing insight in existing knowledge gaps that should again lead to clinical trials with useful endpoints. It is time to extend the plan-do-check-act cycle described by Shewhart/Deming12 and include the guidelines and recommendations to ensure a more rapid transfer of what we know into what we do. NOVEMBER JUOP PAPERS Reviews Suzman et al13 performed a systematic review and meta-analysis on prostate biopsy infections—timing and severity. Sometimes it is difficult to find clear citations on the overall incidence of a treatment like radical prostatectomy or biopsy. I have some seen US estimates of around 80,000 prostatectomies a year. Globally, these authors cite around 3 million prostate biopsies with various rates of related infections. Their review criteria ended with 55 papers and over 24 1000 cases—mostly transrectal. Overall infections in 4% with 0.8% requiring hospitalization, and the most common time interval was 3 days. Key themes discussed included heterogeneity on how infections reported, criteria used, and emerging data and trial comparisons with a transperineal approach. They present a table on recommended reporting criteria for consideration moving forward. Retrospective Study Yamamoto et al14 presented a multicenter retrospective study aimed at real-world outcomes from patients receiving no adjuvant therapy, adjuvant chemotherapy, or adjuvant immunotherapy. From 528 patients and propensity score matching, they calculated disease-free and cancer-specific survival. Both treatment arms were independent predictors of disease-free and cancer-free survival compared with surgery only. The data presented are robust with good use of supplemental analyses links. The Sankey diagram shows the multiple pathways patients may take from staging to postoperative treatment to outcome. Additional analyses suggest more benefit for postoperative treatments in node-positive cases. Yang et al15 performed a retrospective study of the experience with biopsy-free radical prostatectomy. This has been controversial from other papers—this one selected more of a clinically locally advanced population and with propensity weighted adjustments found early time points of urinary control advantage. Palma and Woo16 offer additional editorial comments on this paper. Rare Conditions Yanagida et al17 described a case of self-injury related to a longstanding set of erotic related activities that involved hot water in the urethra and CO2 gas injected under the skin. This particular set of events led to bladder rupture and subcutaneous injuries. Although the bladder exploration and repair was a standard approach, the use of hyperbaric oxygen is creative and successful on a 3-week timeframe. The authors review the indications and physiology of hyperbaric oxygen and present parallel use of laboratory measures such as C-reactive profiles. People, Places, and Things As our lead editorial piece reviewed, the 23rd meeting of the Association of Academic European Urologist met December 4 to 7 in Copenhagen, Denmark. This form mixes the early academic forum as summarized on guidelines, state-of-the-art lectures, and abstracts from members and guests. Figure 1 is a highlight slide from the session, depicting our growing sources of practice changing information. Figures 2-6 show some highlights from the People, Places, and Things from the event.Figure 1.: The evolution of clinical practice guidelines as we have added real-world data, rapid trials, performance monitoring, and expert experience (ex—podcasts).Figure 2.: People—Henk van der Poel leads the morning academic session at the Association of Academic European Urology in Copenhagen, Denmark.Figure 3.: People—Award Winners. A, Anders Bjartell delivered the Michael Marberger Lecture on his research and career in prostate cancer biomarkers. As a Swedish urologist, he has collaborated significantly with the United States with research and visiting scientist positions at the NIH and Memorial Sloan Kettering in New York. B, Juan Palou from Spain (left) won the Laurent Boccon-Gibod award—a career award for the organization and development of urology in Europe. Right—Ian Eardley presented the award as the committee chair.Figure 4.: Places. Magstaede in Copenhagen—a narrow, historic street known for the original cobblestone, curved street, colored buildings, pedestrian friendly, and the experience of walking back in time. Many of the buildings are historic status and cannot be altered.Figure 5.: Places. The 5 star “grand hotel” Hotel d'Angleterre in Copenhagen city center. Note that for a cold, rainy, December night, the city is full of people walking, Christmas shopping, and dinning. As our guide told, us residents like a Parris-like feel for their city and will putting on whatever layers of clothing, heating lamps, and blankets to enjoy an outdoor meal or drink.Figure 6.: Things. A Gala dinner at the Glyptoteket museum ballroom in Copenhagen. Nothing quite matches a black tie dinner in the Glyptoteket central hall—filled with Roman portrait statues.
No takes yet. Share an insight, caveat, or question.
Osther et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: